logo
Are dire wolves de-extinct? Genetically engineered pups spark controversy

Are dire wolves de-extinct? Genetically engineered pups spark controversy

Yahoo09-04-2025

Three genetically engineered wolves that may resemble extinct dire wolves are trotting, sleeping and howling in an undisclosed secure location in the U.S., according to the company that aims to bring back lost species.
The wolf pups, which range in age from three to six months old, have long white hair, muscular jaws and already weigh in at around 80 pounds — on track to reach 140 pounds at maturity, researchers at Colossal Biosciences reported Monday.
Dire wolves, which went extinct more than 10,000 years old, are much larger than gray wolves, their closest living relatives today.
Independent scientists said this latest effort doesn't mean dire wolves are coming back to North American grasslands any time soon.
'All you can do now is make something look superficially like something else'— not fully revive extinct species, said Vincent Lynch, a biologist at the University at Buffalo who was not involved in the research.
Colossal scientists learned about specific traits that dire wolves possessed by examining ancient DNA from fossils. The researchers studied a 13,000 year-old dire wolf tooth unearthed in Ohio and a 72,000 year-old skull fragment found in Idaho, both part of natural history museum collections.
Then the scientists took blood cells from a living gray wolf and used CRISPR to genetically modify them in 20 different sites, said Colossal's chief scientist Beth Shapiro. They transferred that genetic material to an egg cell from a domestic dog. When ready, embryos were transferred to surrogates, also domestic dogs, and 62 days later the genetically engineered pups were born.
Colossal has previously announced similar projects to genetically alter cells from living species to create animals resembling extinct woolly mammoths, dodos and others.
Though the pups may physically resemble young dire wolves, 'what they will probably never learn is the finishing move of how to kill a giant elk or a big deer,' because they won't have opportunities to watch and learn from wild dire wolf parents, said Colossal's chief animal care expert Matt James.
Colossal also reported today that it had cloned four red wolves using blood drawn from wild wolves of the southeastern U.S.'s critically endangered red wolf population. The aim is to bring more genetic diversity into the small population of captive red wolves, which scientists are using to breed and help save the species.
This technology may have broader application for conservation of other species because it's less invasive than other techniques to clone animals, said Christopher Preston, a wildlife expert at the University of Montana who was not involved in the research. But it still requires a wild wolf to be sedated for a blood draw and that's no simple feat, he added.
Colossal CEO Ben Lamm said the team met with officials from the U.S. Interior Department in late March about the project. Interior Secretary Doug Burgum praised the work on X on Monday as a 'thrilling new era of scientific wonder' even as outside scientists said there are limitations to restoring the past.
'Whatever ecological function the dire wolf performed before it went extinct, it can't perform those functions' on today's existing landscapes, said Buffalo's Lynch.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy
GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

Yahoo

time2 hours ago

  • Yahoo

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and efficient cargo delivery platforms, today announced a key milestone in the development of its pipeline: First patient has been dosed in an investigator-initiated trial (IIT) of GEB-101, the Company's leading in vivo genome editing program for TGFBI corneal dystrophy. The ongoing IIT is in collaboration with Prof Xingtao ZHOU, MD, PhD, Professor and President, and his team at the Eye & ENT Hospital of Fudan University in Shanghai, China. GEB-101 is a wholly owned program of GenEditBio. Preclinical assessment in non-human primates demonstrated that GEB-101 was well-tolerated after local intrastromal injection and had high safety profile with virtually undetectable off-target effect ( The preclinical research recently received the Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy in May 2025 ( The IIT of GEB-101 is an open-label and dose-escalation clinical study to investigate the tolerability of GEB-101 when combined with standard treatment phototherapeutic keratectomy in adults with corneal dystrophy. The first patient, who received GEB-101 in May 2025, has been discharged from the collaborating hospital with no observable adverse event. This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy. "Today, on National Sight Day, we are proud and honored to announce that we have initiated the world's first clinical study of an in vivo genome editing investigational therapy for corneal dystrophy. This key milestone represents years of effort in technology platform development and dedication from our world-class research team and clinical partners," said Zongli ZHENG, PhD, Chairman and Co-Founder of GenEditBio, "We stand at the frontier of a new era and recognize the transformative potential of this moment is not just for the Company but for the entire field of genetic medicine because the technology has the potential to extend far beyond corneal dystrophy. Our company is committed to developing fundamentally safe, efficacious and affordable in vivo genome editing therapies for genetic diseases with unmet medical needs". "This investigator-initiated trial marks a defining moment for our award-winning research team and clinical partners. Remarkably, in just one year since initiating our proof-of-concept and preclinical studies, we have successfully integrated our genome editing and delivery technologies to advance this pipeline program from the laboratory to clinical stage, showcasing our competence and dedication to rapidly translate basic research into clinical program to ultimately benefit patients," said Tian ZHU, PhD, CEO and Co-Founder of GenEditBio, "We also express our deepest gratitude to the participant who volunteers in this early stage trial to support medical innovation. As clinical data accumulate, we are positive that GEB-101 has the potential to become a new treatment option for patients with corneal dystrophy". About TGFBI Corneal Dystrophy TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal protein buildup in the stromal layer of cornea. Symptoms include photophobia, gradual vision loss and recurrent corneal erosions. Current treatment options include phototherapeutic keratectomy and corneal transplantation. These procedures, however, have known limitations such as recurrence and carry risks of sight-threatening complications, underscoring the need for novel therapies. About GEB-101 GEB-101, a wholly owned program of GenEditBio, is a genome editing drug candidate designed as a once-and-done treatment for TGFBI corneal dystrophy. GEB-101 is based on the CRISPR-Cas genome editing technology that targets a particular locus in the mutated TGFBI gene. GEB-101 is encapsulated in the form of RNP in engineered protein delivery vehicle (PDV), a proprietary in vivo delivery system developed by GenEditBio. GEB-101 is to be administered by intrastromal injection and is being investigated for tolerability in the IIT. About GenEditBio Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed "DNA surgery") with high safety profile, unmatched precision, and affordable access for genetic diseases with unmet needs. The Company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing lipid nanoparticle (LNP) and engineered protein delivery vehicle (PDV). We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Biotherapeutics, Lumosa Therapeutics, HKSTP Venture Fund, and others. For more information, please visit Related Previous Press Releases GenEditBio Scientist Receives Excellence in Research Award at the 28th Annual Meeting of the American Society of Gene and Cell Therapy 2025 GenEditBio to Present Preclinical Data on its Delivery Technology Platform and Drug Pipeline at the 28th Annual Meeting of the American Society of Gene and Cell Therapy Media Contact: Investors Contact: bd@ View original content: SOURCE GenEditBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Finland's AIATELLA secures funds for AI cardiovascular imaging solutions
Finland's AIATELLA secures funds for AI cardiovascular imaging solutions

Yahoo

time2 hours ago

  • Yahoo

Finland's AIATELLA secures funds for AI cardiovascular imaging solutions

Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI. The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes. Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors. The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging. This multimodal technology identifies abnormalities and quantifies changes over time in those at risk. It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care. AIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK. AIATELLA co-founder and CEO Jack Parker said: 'Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it's too late.' Initially applied to the aorta artery, AIATELLA's vision extends to encompass all blood vessels in the body with its technology. The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms. This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide. The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals. AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups. "Finland's AIATELLA secures funds for AI cardiovascular imaging solutions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The Science Of De-Extinction Is Providing Hope For Nature's Future
The Science Of De-Extinction Is Providing Hope For Nature's Future

Forbes

time20 hours ago

  • Forbes

The Science Of De-Extinction Is Providing Hope For Nature's Future

Younger audiences are becoming increasingly tired with the rhetoric on the horrors of climate change, with research showing that Gen-Z feel that their climate-related concerns are often dismissed by older generations. Enter: Colossal Biosciences, a Texas-based biotech and genetic engineering company working tirelessly to de-extinct several animals and bring hope to the future of nature. Co-founded by entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal Biosciences is tapping into the cultural zeitgeist by not only making bold scientific promises, but by embracing a storytelling approach that resonates with Gen Z. High school students write in asking how they can get involved; college students express inspiration to pursue science because of Colossal Biosciences' work. Their excitement is less about nostalgia and more about agency—about changing the narrative of inevitable loss. 'If history teaches us anything, it's that we shouldn't argue with youth,' Colossal Biosciences CEO Lamm said. 'Progress often begins with what youth culture believes in,' Citing historical youth-led movements, Lamm believes the younger generation is rallying around biotech and conservation innovation. Not only does the company have the backing of Gen-Z, but it has also garnered support from Hollywood's greatest. Peter Jackson, Tom Brady, Tiger Woods, Sophie Turner and George R.R. Martin have all endorsed or invested in Colossal Biosciences. The company is focused on creating a de-extinction toolkit that can act as a fail-safe if the government, conservationists, environmentalists and citizens fail to do what is necessary to protect animal species. By 2050, nearly half of all animal species could be threatened with extinction, which could pose significant impact on the global economy. Colossal Biosciences' mission is to stop or even reverse extinction and, to date, they have announced ambitious projects related to the woolly mammoth, thylacine, dodo and dire wolf. The species selection is driven by an elaborate plan to assist conservationists, environmentalists, governments and organizations all over the world to biobank genetic materials, create resilience in faltering species lines and, if absolutely necessary, recover full species from extinction. 'It goes back to the apathy point in your research that is making everyone feel so hopeless. We need to all be advocating for genetic rescue science to be used and for lots of advancements to be made in order to save species. But, do you know how hard it is to get people to care about progress or the need for progress in genetic science?' Lamm noted. 'Almost impossible. Do you know how easy it is to get people talking about bringing back their favorite ancient pachyderm? Substantially easier,' Lamm explained that he doesn't believe the company's mission can succeed without public support and an interest in and understanding of the new technologies his company is inventing. In early 2025, the company made a breakthrough with the colossal woolly mouse, sharing parts of the woolly mammoth's DNA and proving the scientists' ability to recreate complex genetic combinations that took nature millions of years to create. 'We need to get people excited about saving the planet, so that we have a shot at being able to actually save it. Part of the reason we are working to bring back the woolly mammoth is so that we could get the public to pay attention to genetic science; it's one part: holy s—t how amazing. And one part: you're doing what now?' Lamm explained. 'That combination has allowed us to talk to a lot of people about what we are working on, why it's important for conservation and how they can get involved,' 'It is going to be their planet to care for,' he added. 'We see it as our job to make sure there is something left for them to take care of.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store